Home Cytokines and Immune Cell Markers Soluble IL-2 Receptor Test: Immune Activation, Inflammation, Sarcoidosis, and Lymphoma Risk

Soluble IL-2 Receptor Test: Immune Activation, Inflammation, Sarcoidosis, and Lymphoma Risk

By
Vita Library
-
3
Understand what a soluble IL-2 receptor or sCD25 test measures, why levels rise in HLH, sarcoidosis, lymphoma, infection, and inflammation, and why the result is not disease-specific.

A soluble IL-2 receptor test measures circulating soluble interleukin-2 receptor alpha, also called sIL-2R alpha, sCD25, or soluble CD25. Activated lymphocytes and some other immune or malignant cells release this portion of the high-affinity IL-2 receptor into blood. An elevated result is therefore a marker of immune-cell activation and proliferation, not a disease-specific signal. Clinicians may use it as supporting evidence in hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome, sarcoidosis, autoimmune lymphoproliferative syndrome, selected lymphomas or leukemias, and other inflammatory or infectious conditions. It cannot diagnose sarcoidosis or cancer, estimate “lymphoma risk” in a healthy person, or identify the cause of inflammation by itself. Values vary with the assay, specimen type, units, kidney function, treatment, and timing, so results from different laboratories may not be interchangeable. The test is most useful when ordered for a defined clinical question and interpreted with symptoms, imaging, blood counts, ferritin, organ tests, pathology, microbiology, and serial trends. A normal value does not exclude localized or early disease.

  • Soluble CD25 reflects activation and turnover of IL-2 receptor-bearing immune cells.
  • High levels occur in many inflammatory, infectious, autoimmune, and malignant conditions.
  • In HLH, sCD25 is one supporting criterion and should be combined with the full syndrome evaluation.
  • In sarcoidosis, the result may support activity assessment but cannot replace imaging, exclusion of infection, or biopsy when needed.
  • In lymphoma, the marker may reflect tumor burden or immune activation but is not a screening test for people without clinical suspicion.

Table of Contents

What Soluble IL-2 Receptor Represents

Interleukin-2 is a cytokine that supports T-cell growth, survival, differentiation, and regulatory T-cell maintenance. Its receptor can be assembled from three chains: alpha, beta, and common gamma. The alpha chain is CD25, encoded by IL2RA. CD25 binds IL-2 with low affinity by itself but creates a high-affinity receptor when combined with the beta and gamma chains.

Resting conventional T cells generally express little CD25. After antigen or cytokine stimulation, they increase CD25 so they can respond strongly to IL-2. Regulatory T cells express CD25 continuously because they depend on IL-2 for survival and suppressive function. Activated B cells, natural killer cells, monocytes, and some malignant lymphoid cells can also contribute to soluble receptor production.

The extracellular part of CD25 can be released from the cell surface through proteolytic shedding, and soluble forms may also arise through other processing pathways. The blood concentration reflects a mixture of the number of activated cells, how strongly they express CD25, how much receptor is released, tissue distribution, and clearance.

A high sCD25 result therefore means that IL-2 receptor-related immune activation or cellular turnover is increased somewhere in the body. It does not reveal which cells produced the receptor or whether IL-2 signaling is excessive, deficient, protective, or harmful. The test measures receptor protein, not IL-2 concentration and not a T-cell count.

Soluble CD25 may also influence IL-2 biology by binding cytokine or modifying its availability, but a routine concentration cannot be translated directly into net immune stimulation or suppression. The immune effect depends on receptor complexes, local cytokine concentration, cell type, and tissue environment.

This broad biology explains both the test’s usefulness and its limitation. It can be a sensitive sign of substantial lymphocyte activation, yet the same signal appears in very different conditions. The result becomes meaningful only after the clinical setting narrows the possibilities.

How the Test Is Performed and Reported

The assay is usually performed on serum or plasma using an immunoassay. Depending on the laboratory, the method may be enzyme-linked, chemiluminescent, or bead-based multiplex testing. Antibodies capture and quantify soluble IL-2 receptor alpha in the specimen.

Results may be reported in units per milliliter, picograms per milliliter, or another calibrated unit. These values are not automatically convertible because “units” depend on the assay’s standard and antibody system. A threshold from one laboratory should not be applied to a result generated by another platform.

Reference intervals also vary. Laboratories use different specimen types, calibrators, populations, and analytical designs. A result must be compared with the interval printed by the performing laboratory. When monitoring a trend, using the same laboratory and method reduces false changes caused by platform differences.

The test generally does not require fasting, but the collection instructions should be checked. Hemolysis, lipemia, specimen processing, storage, and transport may affect some assays. Serum and plasma results should not be mixed casually in a longitudinal chart.

Kidney function matters because soluble proteins may accumulate when clearance is reduced. Renal impairment can raise sCD25 independently of the primary inflammatory process and is especially important when interpreting cerebrospinal fluid-to-serum relationships in suspected neurosarcoidosis. Liver disease and broad critical illness can also change production and clearance.

Timing relative to treatment is essential. Corticosteroids, chemotherapy, lymphoma therapy, cytokine-targeted drugs, transplantation, and treatment of infection can lower immune activation. A falling value after therapy may support response, but the clinical outcome and disease-specific tests remain primary.

The test is not the same as flow-cytometric CD25 expression. Flow cytometry shows which circulating cells carry membrane CD25; the soluble assay measures receptor released into fluid. Both may be abnormal for different reasons and should not be substituted for one another.

Use in HLH and Hyperinflammation

Soluble CD25 is one of the eight HLH-2004 diagnostic criteria. HLH is a dangerous syndrome of uncontrolled immune activation that can be familial or secondary to infection, malignancy, rheumatic disease, or other triggers. The clinical pattern includes persistent fever, organ enlargement, cytopenias, liver injury, coagulopathy, high ferritin, high triglycerides, low fibrinogen, neurologic involvement, and organ failure.

In HLH, activated T cells release large amounts of soluble CD25. A marked elevation can support the presence of widespread lymphocyte activation and may help distinguish severe hyperinflammation from more limited illness in the appropriate setting. However, adult studies show that moderate elevations overlap with infection, lymphoma, leukemia, autoimmune disease, and critical illness.

The criterion should never be used alone. A patient does not have HLH solely because sCD25 is high, and a result below the criterion does not safely exclude early, treated, or atypical disease. Clinicians combine it with ferritin trends, blood counts, triglycerides, fibrinogen, liver tests, spleen size, cytotoxic-pathway studies, marrow or tissue findings, and the search for a trigger.

Turnaround time can limit emergency use. Ferritin, complete blood count, liver enzymes, fibrinogen, coagulation studies, and triglycerides are usually available sooner and guide immediate management. Treatment should not be delayed in a rapidly deteriorating patient while a send-out sCD25 result is pending.

The value may also be followed during treatment. Falling levels can indicate reduced T-cell activation, but soluble CD25 may normalize at a different speed from ferritin or organ-function tests. Transfusions, chemotherapy, immunosuppression, and treatment of the trigger complicate the trajectory.

Macrophage activation syndrome is part of the same hyperinflammatory spectrum, especially in Still’s disease, systemic juvenile idiopathic arthritis, lupus, and other rheumatic conditions. An MAS blood test panel prioritizes serial routine markers; sCD25 is supportive when available.

Very high soluble CD25 in HLH may raise concern for a lymphoid malignancy as the trigger, particularly in adults, but the number cannot identify lymphoma. Imaging, pathology, marrow studies, flow cytometry, molecular testing, and infection evaluation are still required.

Use in Sarcoidosis

Sarcoidosis is a granulomatous inflammatory disease that most often affects the lungs and lymph nodes but can involve the eyes, skin, heart, nervous system, liver, spleen, kidneys, and other organs. Activated T cells and macrophages within granulomas can increase soluble IL-2 receptor release.

Serum sCD25 may be elevated in active sarcoidosis and can correlate with disease extent or activity in some populations. Studies have suggested that it may be more sensitive than angiotensin-converting enzyme in selected diagnostic cohorts. Nevertheless, substantial overlap exists with infection, hypersensitivity pneumonitis, pulmonary fibrosis, lymphoma, autoimmune disease, and other inflammatory conditions.

Sarcoidosis remains a clinical diagnosis supported by a compatible presentation and imaging, evidence of noncaseating granulomatous inflammation when tissue is needed, and exclusion of alternative causes. Tuberculosis, fungal infection, occupational or environmental exposure, drug reactions, common variable immunodeficiency-related granulomatous disease, and malignancy can mimic it. A high sCD25 result cannot perform that exclusion.

The marker may be useful for monitoring a person whose baseline value was elevated and tracked with disease. A decline after corticosteroids or other treatment may support response, while a rise can prompt reassessment. Symptoms, lung function, imaging, electrocardiography, cardiac imaging, eye examination, calcium metabolism, and organ-specific tests remain more direct measures. Monitoring should be planned before treatment whenever possible. If the pretreatment value was normal, later normal measurements provide little information about activity. If it was elevated, clinicians should still avoid treating the laboratory value alone. Persistent elevation may reflect residual granulomatous activity, slow biomarker clearance, kidney impairment, infection, or another inflammatory condition. A patient can improve clinically while the marker remains above range, and organ disease can worsen without a dramatic rise. Decisions about corticosteroid dose or additional immunosuppression therefore rely on the threatened organ and objective clearly documented functional change.

A normal value does not exclude isolated cardiac, neurologic, ocular, or skin sarcoidosis. Localized disease may not release enough receptor into blood, and treatment can suppress the level. The sensitivity also depends on the laboratory cutoff and the population being tested.

In suspected neurosarcoidosis, soluble IL-2 receptor has been studied in cerebrospinal fluid and in CSF-to-serum indices. Evidence suggests possible diagnostic value, but methods and cutoffs are not standardized, and infection, lymphoma, multiple sclerosis, and other inflammatory neurologic diseases require careful exclusion.

Kidney impairment can raise serum sCD25 and distort interpretation. Sarcoidosis itself can affect kidney function or calcium balance, so creatinine and estimated filtration should be reviewed when a result appears disproportionately high.

The test is most helpful as one piece of a structured sarcoidosis evaluation. It should not be ordered as a stand-alone screen for fatigue, cough, enlarged lymph nodes, or an abnormal chest image without a plan to investigate competing diagnoses.

Lymphoma, Leukemia, and Lymphoproliferation

Some lymphomas and leukemias express membrane CD25, release soluble receptor, or drive strong surrounding immune activation. High sCD25 has been reported in adult T-cell leukemia/lymphoma, peripheral T-cell lymphomas, diffuse large B-cell lymphoma, Hodgkin lymphoma, and other hematologic malignancies.

In a person with established lymphoma, the level may correlate with tumor burden, stage, inflammatory activity, prognosis, or treatment response in certain disease-specific studies. Its value depends on the lymphoma type and the protocol. It is not a universal replacement for imaging, lactate dehydrogenase, pathology, minimal residual disease testing, or established prognostic indices.

The phrase “lymphoma risk” can be misleading. A high result does not calculate the chance that an otherwise healthy person has or will develop lymphoma. Most elevated results are not specific, and many patients with lymphoma have values that overlap with benign inflammation. Conversely, a normal value does not rule out lymphoma.

Clinical concern for lymphoma comes from persistent or enlarging lymph nodes, unexplained fever, drenching night sweats, weight loss, itching, cytopenias, organ enlargement, abnormal imaging, a clonal blood population, or tissue findings. Excisional or core biopsy with morphology, immunohistochemistry, flow cytometry, and molecular studies establishes the diagnosis.

Autoimmune lymphoproliferative syndrome can also raise soluble CD25. ALPS involves defective lymphocyte apoptosis, chronic nonmalignant lymph-node or spleen enlargement, autoimmune cytopenias, and increased double-negative T cells. Soluble CD25 is one biomarker among a broader diagnostic evaluation and does not distinguish ALPS from lymphoma by itself.

During lymphoma treatment, sCD25 may fall with response. A persistent or rising level can prompt reassessment but can also reflect infection, treatment-related inflammation, organ dysfunction, or another immune process. The trend should be compared with disease-specific measures.

A very high value in a patient with fever, cytopenias, liver dysfunction, and splenomegaly may indicate lymphoma-associated HLH. This is an emergency requiring simultaneous hyperinflammation treatment and an urgent search for the malignancy. The marker supports the syndrome but does not identify the lymphoma subtype.

Other Causes of a High Result

Infections can activate T cells and raise soluble CD25. Viral illnesses such as Epstein–Barr virus, cytomegalovirus, HIV, and severe systemic viral infection may increase the result. Bacterial, fungal, and parasitic diseases can do the same, especially when inflammation is widespread.

Autoimmune and inflammatory disorders associated with elevation include lupus, rheumatoid arthritis, inflammatory bowel disease, autoimmune liver disease, multiple sclerosis, vasculitis, graft-versus-host disease, and granulomatous conditions. The degree of elevation varies and does not map to one universal activity scale.

Transplantation can increase sCD25 during immune activation, infection, graft-versus-host disease, or rejection. Modern transplant monitoring uses organ function, donor-specific antibodies, chimerism, drug levels, viral testing, biopsy, and other validated measures. Soluble CD25 is supportive rather than definitive.

Common variable immunodeficiency and other inborn errors of immunity can produce chronic immune activation, granulomatous disease, lymphoproliferation, or infection, all of which may raise the marker. A high result in an immunodeficient patient should not automatically be attributed to one process.

Tissue injury, liver disease, kidney dysfunction, and critical illness add further overlap. Medicines can suppress or stimulate immune-cell activation. Because the list is broad, ordering the test without a focused differential often produces an elevated but nonactionable result.

A mild increase is especially nonspecific. The probability of a serious disorder depends much more on symptoms, examination, blood counts, imaging, organ tests, and the persistence of the abnormality than on a small departure from the reference interval.

The result should not be used to diagnose “chronic inflammation” in isolation. Established markers such as C-reactive protein, erythrocyte sedimentation rate, ferritin, complete blood count, and organ-specific studies are usually faster and easier to interpret. A standard inflammatory marker panel answers a different question from T-cell activation.

Limitations, Normal Results, and Testing Pitfalls

A normal or low soluble CD25 result usually means that the assay did not detect increased systemic receptor concentration at that time. It does not prove that T cells are inactive or that sarcoidosis, lymphoma, infection, or HLH is absent. Localized disease, early disease, partial treatment, or assay-specific sensitivity can produce a non-elevated value.

Low values are rarely interpreted as a deficiency state. The test is not designed to diagnose inherited CD25 deficiency or impaired IL-2 signaling. Those conditions require lymphocyte phenotyping, functional studies, and IL2RA genetic testing.

Reference limits differ markedly among laboratories. Units per milliliter and picograms per milliliter should not be converted using a generic factor. A published HLH or sarcoidosis cutoff must match the method before it is applied.

Renal dysfunction can elevate the level and reduce specificity. Age, immune activation, specimen type, timing, and treatment also influence interpretation. The clinician should confirm whether the result came from serum or plasma and whether serial tests used the same platform.

Biotin or heterophile antibodies can interfere with some immunoassays, depending on design. The performing laboratory can advise when a result is inconsistent with the clinical picture. Reanalysis, dilution studies, or an alternate platform may be appropriate.

A single extreme value may be real but still nonspecific. It should trigger assessment for severe immune activation, hematologic malignancy, infection, HLH, or organ dysfunction rather than an automatic diagnosis. Conversely, repeating the same test without investigating the cause adds little.

The name can cause confusion with soluble IL-2 itself, membrane CD25 flow cytometry, and anti-IL-2 receptor antibodies used as medicines. The report should identify soluble IL-2 receptor alpha or soluble CD25 explicitly.

Follow-Up and Practical Interpretation

Start with the reason the test was ordered. For suspected HLH, interpret it with fever, organ enlargement, ferritin, cytopenias, triglycerides, fibrinogen, liver tests, coagulation, natural killer-cell and degranulation studies, and the search for infection or malignancy. Do not wait for sCD25 before escalating care in a rapidly worsening patient.

For suspected sarcoidosis, review chest imaging, organ symptoms, pulmonary function, calcium, kidney and liver tests, electrocardiography, eye evaluation, exposure history, and microbiology. Biopsy is often needed when the presentation is not classic or when infection and malignancy must be excluded.

For possible lymphoma, the appropriate next steps may include complete blood count and smear, lactate dehydrogenase, imaging, diagnostic flow cytometry, marrow examination, or lymph-node biopsy. Soluble CD25 can support burden assessment but cannot replace tissue diagnosis.

When following a known condition, record the baseline value, laboratory method, treatment dates, kidney function, and concurrent infection. A falling trend is useful only if it parallels meaningful clinical improvement. Discordance should prompt investigation rather than automatic treatment adjustment.

A practical interpretation might state: soluble IL-2 receptor alpha is markedly elevated, indicating substantial immune-cell activation; the result is compatible with but not specific for the suspected condition; renal impairment may contribute; and disease-specific evaluation is required. That language is safer than “positive for sarcoidosis” or “high lymphoma risk.”

Repeat testing is reasonable when the initial specimen was compromised, the method changed, or a validated disease-monitoring plan uses serial values. It is less useful as frequent surveillance in someone without a diagnosis or compatible symptoms.

Seek urgent medical care for persistent fever with confusion, breathing difficulty, bleeding, low blood pressure, jaundice, rapidly falling blood counts, or other signs of organ dysfunction. In that setting, sCD25 is a supporting biomarker within an emergency assessment, not a result to interpret at home.

The central meaning is activation, not identity. The test tells clinicians that CD25-bearing cells are releasing more soluble receptor than expected. The patient’s history, organ findings, pathology, microbiology, and trends determine why that activation is occurring and what should be done next.

References

Disclaimer

This article is for general education and does not diagnose HLH, sarcoidosis, lymphoma, leukemia, infection, or another inflammatory disorder. Soluble IL-2 receptor results require assay-specific interpretation with kidney function, treatment timing, symptoms, imaging, pathology, microbiology, and other laboratory findings. Severe persistent fever or signs of organ dysfunction require urgent medical evaluation.

RELATED ARTICLESMORE FROM AUTHOR